Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.

Adès, L; Eclache, V; Gardin, C; Boehrer, S; Leroux, G; Martiat, P; Fenaux, P

Adès, L; Eclache, V; Gardin, C; Boehrer, S; Leroux, G; Martiat, P; Fenaux, P.

Bone Marrow Transplant ; 45(4): 791-2, 2010 Apr.

Article in En | MEDLINE | ID: mdl-19718061

Subject(s)

Antineoplastic Agents/therapeutic use; Hematopoietic Stem Cell Transplantation; Leukemia, Myeloid, Acute/drug therapy; Neoplasm Recurrence, Local/drug therapy; Thalidomide/analogs & derivatives; Transplantation Conditioning/methods; Aged; Chromosomes, Human, Pair 5/genetics; Female; Gene Deletion; Humans; Lenalidomide; Leukemia, Myeloid, Acute/genetics; Remission Induction; Thalidomide/therapeutic use; Transplantation Chimera; Transplantation, Homologous

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning / Neoplasm Recurrence, Local / Antineoplastic Agents Limits: Aged / Female / Humans Language: En Journal: Bone Marrow Transplant Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google